Actuate Therapeutics’ (ACTU) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ FY2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at $0.11 EPS.

A number of other equities analysts have also commented on the stock. B. Riley started coverage on shares of Actuate Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $20.00 target price on the stock. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $20.33.

Actuate Therapeutics Stock Down 5.3%

Shares of NASDAQ:ACTU opened at $6.65 on Tuesday. The firm’s 50 day simple moving average is $7.53 and its 200-day simple moving average is $7.93. Actuate Therapeutics has a one year low of $5.47 and a one year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.11).

Institutional Investors Weigh In On Actuate Therapeutics

Several institutional investors have recently bought and sold shares of the company. BIOS Capital Management LP boosted its stake in Actuate Therapeutics by 0.7% in the second quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company’s stock valued at $60,887,000 after acquiring an additional 71,428 shares in the last quarter. Voss Capital LP boosted its stake in Actuate Therapeutics by 101.0% in the second quarter. Voss Capital LP now owns 286,140 shares of the company’s stock valued at $1,748,000 after acquiring an additional 143,759 shares in the last quarter. Geode Capital Management LLC boosted its stake in Actuate Therapeutics by 252.5% in the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after acquiring an additional 84,561 shares in the last quarter. Sigma Planning Corp boosted its stake in Actuate Therapeutics by 47.3% in the first quarter. Sigma Planning Corp now owns 23,675 shares of the company’s stock valued at $160,000 after acquiring an additional 7,600 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after acquiring an additional 11,105 shares in the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.